KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Cash & Current Investments (2016 - 2025)

CRISPR Therapeutics AG's Cash & Current Investments history spans 11 years, with the latest figure at $2.0 billion for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 3.78% year-over-year to $2.0 billion; the TTM value through Dec 2025 reached $2.0 billion, up 3.78%, while the annual FY2025 figure was $2.0 billion, 3.78% up from the prior year.
  • Cash & Current Investments for Q4 2025 was $2.0 billion at CRISPR Therapeutics AG, up from $1.9 billion in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $2.6 billion in Q2 2021 and bottomed at $1.7 billion in Q4 2023.
  • The 5-year median for Cash & Current Investments is $1.9 billion (2024), against an average of $2.0 billion.
  • The largest annual shift saw Cash & Current Investments skyrocketed 174.0% in 2021 before it fell 23.7% in 2022.
  • A 5-year view of Cash & Current Investments shows it stood at $2.4 billion in 2021, then decreased by 23.7% to $1.8 billion in 2022, then dropped by 6.7% to $1.7 billion in 2023, then grew by 12.41% to $1.9 billion in 2024, then grew by 3.78% to $2.0 billion in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Cash & Current Investments are $2.0 billion (Q4 2025), $1.9 billion (Q3 2025), and $1.7 billion (Q2 2025).